Dosing & Uses
Dosage Forms & Strengths
tablet, extended release
- 10mg
Benign Prostatic Hyperplasia (BPH)
10 mg PO qDay taken after same meal
Safety & efficacy not established
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (30)
- atazanavir
atazanavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- ceritinib
ceritinib and alfuzosin both increase QTc interval. Contraindicated.
- chloramphenicol
chloramphenicol will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- cisapride
alfuzosin and cisapride both increase QTc interval. Contraindicated.
- clarithromycin
alfuzosin and clarithromycin both increase QTc interval. Contraindicated.
- cobicistat
cobicistat will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased alfuzosin concentrations, which can result in serious or life threatening reactions such as hypotension
- darunavir
darunavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious and/or life-threatening reactions.
- dronedarone
alfuzosin and dronedarone both increase QTc interval. Contraindicated.
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
- fluconazole
alfuzosin and fluconazole both increase QTc interval. Contraindicated.
- fosamprenavir
fosamprenavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- idelalisib
idelalisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- indinavir
indinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- itraconazole
itraconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.
alfuzosin and itraconazole both increase QTc interval. Contraindicated. - ketoconazole
ketoconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.
- lefamulin
lefamulin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.
- levoketoconazole
levoketoconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.
- lopinavir
lopinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- mifepristone
mifepristone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- nefazodone
nefazodone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- nelfinavir
nelfinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- nirmatrelvir
nirmatrelvir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.
- nirmatrelvir/ritonavir
nirmatrelvir/ritonavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Nirmatrelvir/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions.
- ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)
ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk for hypotensio
- posaconazole
alfuzosin and posaconazole both increase QTc interval. Contraindicated.
- ritonavir
ritonavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- saquinavir
saquinavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. .
alfuzosin and saquinavir both increase QTc interval. Contraindicated. - thioridazine
alfuzosin and thioridazine both increase QTc interval. Contraindicated.
- tipranavir
tipranavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.
- voriconazole
alfuzosin and voriconazole both increase QTc interval. Contraindicated.
Serious - Use Alternative (81)
- amiodarone
alfuzosin and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
- amisulpride
amisulpride and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- anagrelide
alfuzosin and anagrelide both increase QTc interval. Avoid or Use Alternate Drug.
- apalutamide
apalutamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
- arsenic trioxide
alfuzosin and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
alfuzosin and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine
alfuzosin and asenapine both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine transdermal
asenapine transdermal and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug.
- azithromycin
alfuzosin and azithromycin both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine
alfuzosin and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug.
- ceritinib
ceritinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
- chlorpromazine
alfuzosin and chlorpromazine both increase QTc interval. Avoid or Use Alternate Drug.
- citalopram
alfuzosin and citalopram both increase QTc interval. Avoid or Use Alternate Drug.
- crizotinib
alfuzosin and crizotinib both increase QTc interval. Avoid or Use Alternate Drug.
- desflurane
desflurane and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug.
- disopyramide
alfuzosin and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.
- dofetilide
alfuzosin and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
- droperidol
alfuzosin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- efavirenz
efavirenz will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- encorafenib
alfuzosin and encorafenib both increase QTc interval. Avoid or Use Alternate Drug.
- entrectinib
alfuzosin and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- enzalutamide
enzalutamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- eribulin
alfuzosin and eribulin both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin base
alfuzosin and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
alfuzosin and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
alfuzosin and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
alfuzosin and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- etravirine
etravirine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- fexinidazole
fexinidazole and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.
fexinidazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates. - flecainide
alfuzosin and flecainide both increase QTc interval. Avoid or Use Alternate Drug.
- foscarnet
alfuzosin and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.
- glasdegib
alfuzosin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- hydroxychloroquine sulfate
hydroxychloroquine sulfate and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug.
alfuzosin and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug. - ibutilide
alfuzosin and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.
- iloperidone
alfuzosin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.
- inotuzumab
inotuzumab and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
alfuzosin and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug. - isoflurane
alfuzosin and isoflurane both increase QTc interval. Avoid or Use Alternate Drug.
- isoniazid
isoniazid will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- ivosidenib
ivosidenib and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
ivosidenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. - lofexidine
alfuzosin and lofexidine both increase QTc interval. Avoid or Use Alternate Drug.
- lonafarnib
lonafarnib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.
- macimorelin
macimorelin and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- methadone
alfuzosin and methadone both increase QTc interval. Avoid or Use Alternate Drug.
- midostaurin
alfuzosin and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.
- mifepristone
mifepristone and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Use alternatives if available
alfuzosin and mifepristone both increase QTc interval. Contraindicated. - mobocertinib
mobocertinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently
- moxifloxacin
alfuzosin and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nilotinib
alfuzosin and nilotinib both decrease QTc interval. Avoid or Use Alternate Drug.
- ondansetron
alfuzosin and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
- osimertinib
alfuzosin and osimertinib both increase QTc interval. Avoid or Use Alternate Drug.
- oxaliplatin
alfuzosin and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug.
- paliperidone
alfuzosin and paliperidone both increase QTc interval. Avoid or Use Alternate Drug.
- panobinostat
alfuzosin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- pazopanib
alfuzosin and pazopanib both increase QTc interval. Avoid or Use Alternate Drug.
- pentamidine
alfuzosin and pentamidine both increase QTc interval. Avoid or Use Alternate Drug.
- pimavanserin
alfuzosin and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.
- pimozide
alfuzosin and pimozide both increase QTc interval. Contraindicated.
- pitolisant
alfuzosin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- ponesimod
alfuzosin and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.
- procainamide
alfuzosin and procainamide both increase QTc interval. Avoid or Use Alternate Drug.
- propafenone
alfuzosin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.
- quetiapine
alfuzosin and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.
- quinidine
alfuzosin and quinidine both increase QTc interval. Avoid or Use Alternate Drug.
- quinine
alfuzosin and quinine both increase QTc interval. Avoid or Use Alternate Drug.
- ribociclib
alfuzosin and ribociclib both increase QTc interval. Contraindicated.
- sevoflurane
alfuzosin and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug.
- sildenafil
sildenafil increases effects of alfuzosin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.
- siponimod
alfuzosin and siponimod both increase QTc interval. Avoid or Use Alternate Drug.
- sorafenib
alfuzosin and sorafenib both increase QTc interval. Avoid or Use Alternate Drug.
- sotalol
alfuzosin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.
- tamsulosin
alfuzosin, tamsulosin. Either increases effects of the other by additive vasodilation. Avoid or Use Alternate Drug. Risk of hypotension.
- tetrabenazine
alfuzosin and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.
- toremifene
alfuzosin and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
- umeclidinium bromide/vilanterol inhaled
alfuzosin and umeclidinium bromide/vilanterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated
- vandetanib
alfuzosin and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.
- vardenafil
vardenafil increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.
- vemurafenib
alfuzosin and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.
- vilanterol/fluticasone furoate inhaled
alfuzosin and vilanterol/fluticasone furoate inhaled both increase QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated
- voxelotor
voxelotor will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
- yohimbe
yohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.
- ziprasidone
alfuzosin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (242)
- acebutolol
alfuzosin and acebutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.
- aceclofenac
aceclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- acemetacin
acemetacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- aldesleukin
aldesleukin increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- amifostine
amifostine, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.
- amitriptyline
amitriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and amitriptyline both increase QTc interval. Use Caution/Monitor. - amlodipine
alfuzosin and amlodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- apomorphine
apomorphine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and apomorphine both decrease QTc interval. Use Caution/Monitor. - arformoterol
arformoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and arformoterol both increase QTc interval. Use Caution/Monitor. - aripiprazole
aripiprazole and alfuzosin both increase QTc interval. Use Caution/Monitor.
- artemether
artemether and alfuzosin both increase QTc interval. Use Caution/Monitor.
- asenapine
alfuzosin and asenapine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- aspirin
aspirin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- aspirin rectal
aspirin rectal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- aspirin/citric acid/sodium bicarbonate
aspirin/citric acid/sodium bicarbonate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- atenolol
alfuzosin and atenolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- atomoxetine
atomoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- avanafil
avanafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- azithromycin
azithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- bedaquiline
alfuzosin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- belzutifan
belzutifan will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information.
- benazepril
benazepril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
alfuzosin increases effects of benazepril by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension. - betaxolol
alfuzosin and betaxolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- bisoprolol
alfuzosin and bisoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- buprenorphine buccal
buprenorphine buccal and alfuzosin both increase QTc interval. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and alfuzosin both increase QTc interval. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and alfuzosin both increase QTc interval. Use Caution/Monitor.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and alfuzosin both increase QTc interval. Use Caution/Monitor.
- captopril
captopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
alfuzosin increases effects of captopril by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood pressure. Monitor blood pressure. - carbamazepine
carbamazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- carbidopa
carbidopa increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Monitor for hypotension.
- carvedilol
alfuzosin and carvedilol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- celecoxib
celecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- celiprolol
alfuzosin and celiprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- cenobamate
cenobamate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.
- chlorpromazine
chlorpromazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- choline magnesium trisalicylate
choline magnesium trisalicylate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- cimetidine
cimetidine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ciprofloxacin
ciprofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and ciprofloxacin both increase QTc interval. Use Caution/Monitor. - citalopram
citalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.
- clarithromycin
clarithromycin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
clarithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor. - clevidipine
alfuzosin and clevidipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- clomipramine
clomipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- clozapine
clozapine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and clozapine both increase QTc interval. Use Caution/Monitor. - crizotinib
crizotinib increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
crizotinib and alfuzosin both increase QTc interval. Use Caution/Monitor. - crofelemer
crofelemer increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.
- dabrafenib
dabrafenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
- dasatinib
dasatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and dasatinib both increase QTc interval. Use Caution/Monitor. - deferasirox
deferasirox will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- degarelix
degarelix and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and degarelix both decrease QTc interval. Use Caution/Monitor. - delafloxacin
delafloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- desipramine
desipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and desipramine both increase QTc interval. Use Caution/Monitor. - deutetrabenazine
alfuzosin and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- diclofenac
diclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- diflunisal
diflunisal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- diltiazem
diltiazem will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased exposure to alfuzosin may be expected when alfuzosin is concomitantly used with diltiazem. Monitor pulse and blood pressure.
- dofetilide
dofetilide and alfuzosin both increase QTc interval. Use Caution/Monitor.
- dolasetron
dolasetron and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and dolasetron both increase QTc interval. Use Caution/Monitor. - donepezil
donepezil and alfuzosin both increase QTc interval. Use Caution/Monitor.
- doxazosin
alfuzosin and doxazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- doxepin
doxepin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- droperidol
droperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.
- duvelisib
duvelisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.
- efavirenz
efavirenz and alfuzosin both increase QTc interval. Use Caution/Monitor.
- elagolix
elagolix will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
- eliglustat
alfuzosin and eliglustat both increase QTc interval. Use Caution/Monitor.
- enalapril
enalapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- encorafenib
encorafenib, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
encorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor. - eribulin
eribulin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- erythromycin base
erythromycin base will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
erythromycin base and alfuzosin both increase QTc interval. Use Caution/Monitor. - erythromycin ethylsuccinate
erythromycin ethylsuccinate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
erythromycin ethylsuccinate and alfuzosin both increase QTc interval. Use Caution/Monitor. - erythromycin lactobionate
erythromycin lactobionate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
erythromycin lactobionate and alfuzosin both increase QTc interval. Use Caution/Monitor. - erythromycin stearate
erythromycin stearate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
erythromycin stearate and alfuzosin both increase QTc interval. Use Caution/Monitor. - escitalopram
escitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and escitalopram both increase QTc interval. Use Caution/Monitor. - esmolol
alfuzosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.
- etodolac
etodolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- fedratinib
fedratinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
- felodipine
alfuzosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- fenoprofen
fenoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- fingolimod
fingolimod and alfuzosin both increase QTc interval. Use Caution/Monitor.
- fluoxetine
alfuzosin and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
fluoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor. - fluphenazine
fluphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and fluphenazine both increase QTc interval. Use Caution/Monitor. - flurbiprofen
flurbiprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- fluvoxamine
fluvoxamine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- formoterol
formoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and formoterol both increase QTc interval. Use Caution/Monitor. - foscarnet
foscarnet and alfuzosin both increase QTc interval. Use Caution/Monitor.
- fosinopril
fosinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- fostemsavir
alfuzosin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- gemifloxacin
gemifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and gemifloxacin both increase QTc interval. Use Caution/Monitor. - gemtuzumab
alfuzosin and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gepirone
gepirone and alfuzosin both increase QTc interval. Modify Therapy/Monitor Closely.
- gilteritinib
alfuzosin and gilteritinib both increase QTc interval. Use Caution/Monitor.
- goserelin
goserelin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- granisetron
alfuzosin and granisetron both increase QTc interval. Use Caution/Monitor.
- haloperidol
haloperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and haloperidol both increase QTc interval. Use Caution/Monitor. - histrelin
histrelin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- hydroxyzine
alfuzosin and hydroxyzine both increase QTc interval. Use Caution/Monitor.
- ibuprofen
ibuprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- ibuprofen IV
ibuprofen IV decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- iloperidone
iloperidone increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor.
iloperidone increases effects of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4. - imidapril
imidapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- indacaterol, inhaled
indacaterol, inhaled and alfuzosin both increase QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
alfuzosin and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor. - indapamide
indapamide and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and indapamide both increase QTc interval. Use Caution/Monitor. - indomethacin
indomethacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- isradipine
alfuzosin and isradipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
isradipine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and isradipine both increase QTc interval. Use Caution/Monitor. - istradefylline
istradefylline will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
- ketoconazole
ketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ketoprofen
ketoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- ketorolac
ketorolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- ketorolac intranasal
ketorolac intranasal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- labetalol
alfuzosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- lapatinib
lapatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and lapatinib both increase QTc interval. Use Caution/Monitor. - lenacapavir
lenacapavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
- lenvatinib
alfuzosin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- letermovir
letermovir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- leuprolide
leuprolide and alfuzosin both increase QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes
- levalbuterol
alfuzosin and levalbuterol both increase QTc interval. Use Caution/Monitor.
- levofloxacin
levofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and levofloxacin both increase QTc interval. Use Caution/Monitor. - levoketoconazole
levoketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lisinopril
lisinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- lithium
alfuzosin and lithium both increase QTc interval. Use Caution/Monitor.
- lofexidine
lofexidine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- loperamide
alfuzosin and loperamide both increase QTc interval. Use Caution/Monitor.
- lopinavir
lopinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.
- lorlatinib
lorlatinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lornoxicam
lornoxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- lumefantrine
lumefantrine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- lurasidone
lurasidone increases effects of alfuzosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.
- maprotiline
maprotiline and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and maprotiline both increase QTc interval. Use Caution/Monitor. - maraviroc
maraviroc, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.
- meclofenamate
meclofenamate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- mefenamic acid
mefenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- mefloquine
mefloquine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and mefloquine both increase QTc interval. Use Caution/Monitor. - meloxicam
meloxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- methadone
methadone and alfuzosin both increase QTc interval. Use Caution/Monitor.
- metoprolol
alfuzosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- mirtazapine
alfuzosin and mirtazapine both increase QTc interval. Use Caution/Monitor.
- mitotane
mitotane decreases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
- moexipril
moexipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- moxifloxacin
moxifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- moxisylyte
alfuzosin and moxisylyte both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- nabumetone
nabumetone decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- nadolol
alfuzosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- naproxen
naproxen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- nebivolol
alfuzosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- nevirapine
nevirapine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nicardipine
alfuzosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- nifedipine
alfuzosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- nilotinib
nilotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- nisoldipine
alfuzosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- nitroglycerin rectal
nitroglycerin rectal, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .
- nortriptyline
nortriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and nortriptyline both increase QTc interval. Use Caution/Monitor. - octreotide
octreotide and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and octreotide both increase QTc interval. Use Caution/Monitor. - ofloxacin
ofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and ofloxacin both increase QTc interval. Use Caution/Monitor. - olanzapine
olanzapine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and olanzapine both increase QTc interval. Use Caution/Monitor. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances - olodaterol inhaled
alfuzosin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- ondansetron
ondansetron and alfuzosin both increase QTc interval. Use Caution/Monitor.
- osilodrostat
osilodrostat and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and osilodrostat both increase QTc interval. Use Caution/Monitor. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval - osimertinib
osimertinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- oxaliplatin
oxaliplatin will increase the level or effect of alfuzosin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- oxaprozin
oxaprozin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- oxymetazoline topical
oxymetazoline topical increases and alfuzosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ozanimod
ozanimod and alfuzosin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
paliperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.
- panobinostat
panobinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.
- parecoxib
parecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- paroxetine
paroxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- pasireotide
alfuzosin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
pasireotide and alfuzosin both increase QTc interval. Use Caution/Monitor. - pazopanib
pazopanib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- penbutolol
alfuzosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- pentamidine
pentamidine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- perindopril
perindopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- perphenazine
perphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and perphenazine both increase QTc interval. Use Caution/Monitor. - phenoxybenzamine
alfuzosin and phenoxybenzamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- phentolamine
alfuzosin and phentolamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- pimavanserin
pimavanserin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- pimozide
pimozide and alfuzosin both increase QTc interval. Use Caution/Monitor.
- pindolol
alfuzosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- piroxicam
piroxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- pitolisant
pitolisant and alfuzosin both increase QTc interval. Use Caution/Monitor.
- posaconazole
posaconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.
- prazosin
alfuzosin and prazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- primaquine
alfuzosin and primaquine both increase QTc interval. Use Caution/Monitor.
- procainamide
procainamide and alfuzosin both increase QTc interval. Use Caution/Monitor.
- propafenone
propafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.
- propranolol
alfuzosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.
- protriptyline
protriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and protriptyline both increase QTc interval. Use Caution/Monitor. - pseudoephedrine
pseudoephedrine decreases effects of alfuzosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- quetiapine
quetiapine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- quinapril
quinapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- quinidine
quinidine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- quizartinib
quizartinib, alfuzosin. Either increases effects of the other by QTc interval. Modify Therapy/Monitor Closely. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs.
- ramipril
ramipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- ranolazine
ranolazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and ranolazine both increase QTc interval. Use Caution/Monitor. - ribociclib
ribociclib and alfuzosin both increase QTc interval. Use Caution/Monitor.
ribociclib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. - rifabutin
rifabutin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- rifampin
rifampin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- rilpivirine
rilpivirine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and rilpivirine both increase QTc interval. Use Caution/Monitor. - risperidone
risperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and risperidone both increase QTc interval. Use Caution/Monitor. - romidepsin
romidepsin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and romidepsin both increase QTc interval. Use Caution/Monitor. - rucaparib
rucaparib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.
- salicylates (non-asa)
salicylates (non-asa) decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- salmeterol
alfuzosin and salmeterol both increase QTc interval. Use Caution/Monitor.
- salsalate
salsalate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- saquinavir
saquinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.
- selpercatinib
selpercatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- sertraline
sertraline and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and sertraline both increase QTc interval. Use Caution/Monitor. - silodosin
alfuzosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- solifenacin
solifenacin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and solifenacin both increase QTc interval. Use Caution/Monitor. - sorafenib
sorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- sotalol
alfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.
sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor. - St John's Wort
St John's Wort will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- stiripentol
stiripentol, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.
- sulfasalazine
sulfasalazine decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- sulindac
sulindac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- sunitinib
sunitinib and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and sunitinib both increase QTc interval. Use Caution/Monitor. - tacrolimus
tacrolimus and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and tacrolimus both increase QTc interval. Use Caution/Monitor. - tadalafil
tadalafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- tazemetostat
tazemetostat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tecovirimat
tecovirimat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
- telavancin
telavancin and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and telavancin both increase QTc interval. Use Caution/Monitor. - terazosin
alfuzosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- tetrabenazine
tetrabenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- thioridazine
thioridazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- timolol
alfuzosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.
- tolfenamic acid
tolfenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- tolmetin
tolmetin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.
- toremifene
toremifene and alfuzosin both increase QTc interval. Use Caution/Monitor.
- trandolapril
trandolapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.
- triclabendazole
alfuzosin and triclabendazole both increase QTc interval. Use Caution/Monitor.
- trimipramine
trimipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and trimipramine both increase QTc interval. Use Caution/Monitor. - triptorelin
triptorelin and alfuzosin both increase QTc interval. Use Caution/Monitor.
- valbenazine
valbenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.
- vandetanib
vandetanib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- vardenafil
vardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and vardenafil both increase QTc interval. Use Caution/Monitor. - vemurafenib
vemurafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.
- verapamil
alfuzosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.
- voclosporin
voclosporin, alfuzosin. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
voriconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.
- vorinostat
vorinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and vorinostat both increase QTc interval. Use Caution/Monitor. - ziprasidone
ziprasidone and alfuzosin both increase QTc interval. Use Caution/Monitor.
- zotepine
alfuzosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor.
Minor (59)
- acetazolamide
acetazolamide will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- amobarbital
amobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- anastrozole
anastrozole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- aprepitant
aprepitant will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- armodafinil
armodafinil will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- artemether/lumefantrine
artemether/lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- bosentan
bosentan will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- brimonidine
brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.
- budesonide
budesonide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- butabarbital
butabarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- butalbital
butalbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- butcher's broom
alfuzosin, butcher's broom. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.
- chloroquine
chloroquine and alfuzosin both increase QTc interval. Minor/Significance Unknown.
- conivaptan
conivaptan will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- cortisone
cortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- cyclophosphamide
cyclophosphamide will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- cyclosporine
cyclosporine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- darifenacin
darifenacin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dasatinib
dasatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dexamethasone
dexamethasone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- DHEA, herbal
DHEA, herbal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dronedarone
dronedarone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ethanol
alfuzosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.
- fluconazole
fluconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- fludrocortisone
fludrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- fosaprepitant
fosaprepitant will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- fosphenytoin
fosphenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- grapefruit
grapefruit will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- griseofulvin
griseofulvin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- hydrocortisone
hydrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- lapatinib
lapatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- larotrectinib
larotrectinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- lumefantrine
lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- marijuana
marijuana will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- methylprednisolone
methylprednisolone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- metronidazole
metronidazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- miconazole vaginal
miconazole vaginal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- nifedipine
nifedipine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- nilotinib
nilotinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- oxcarbazepine
oxcarbazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- pentobarbital
pentobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- phenobarbital
phenobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- phenylephrine
alfuzosin, phenylephrine. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.
- phenylephrine PO
alfuzosin, phenylephrine PO. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.
- phenytoin
phenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- posaconazole
posaconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- prednisone
prednisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- primidone
primidone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- quinupristin/dalfopristin
quinupristin/dalfopristin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- rifapentine
rifapentine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- rufinamide
rufinamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- secobarbital
secobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- tizanidine
tizanidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.
- topiramate
topiramate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- treprostinil
treprostinil increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.
- verapamil
verapamil will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- voriconazole
voriconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- zafirlukast
zafirlukast will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
Adverse Effects
1-10%
Abdominal pain (1-2%)
Back pain (1-2%)
Brochitis (1-2%)
Constipation (1-2%)
Dizziness (5.7%)
Dyspepsia (1-2%)
Fatigue (2.7%)
Headache (3%)
Impotence (1-2%)
Nausea (1-2%)
Pharyngitis (1-2%)
URT infection (3%)
Sinusitis (1-2%)
Upper respiratory infection (3%)
Postmarketing Reports
General disorders: Edema
Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation
Gastrointestinal disorders: Diarrhea, vomiting
Hepatobiliary disorders: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)
Upper respiratory system: Rhinitis
Reproductive system: Priapism
Dermatology: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis
Vascular disorders: Flushing
Blood and lymphatic system disorders: Thrombocytopenia
Warnings
Contraindications
Hypersensitivity
Moderate to severe liver impairment
Coadministration with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other alpha1-blocking agents
Cautions
Caution in coronary artery disease, liver disease, symptomatic orthostatic hypotension or coadministration with other drugs that lower blood pressure
May cause syncope (first-dose effect)
Discontinue treatment if angina occurs or worsens
Rule out prostate cancer before initiating therapy (symptoms similar)
Priapism may occur with use
Rule out prostate cancer prior to treatment
Caution with renal impairment (ieg, CrCl <30 mL/min)
Caution with history of prolonged QT syndrome (shown to prolong QT interval)
Intraoperative floppy iris syndrome during cataract surgery reported Advise patient regarding risk of priapism
Do not chew or crush tablets
Not for use as antihypertensive drug
Pregnancy & Lactation
Pregnancy
Drug is not indicated for use in women; there are no adequate data on developmental risk associated with use in pregnant women
Animal data
- Based on findings from animal studies, alfuzosin administered during the period of organogenesis was not teratogenic, embryotoxic or fetotoxic at up to 1200 times the MRHD of 10 mg via AUC in rats and 3 times in rabbits, via body surface area
Lactation
Drug is not indicated for use in women; there are no data on presence in human milk, effect on breastfed child, or on milk production
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Selective antagonist of postsynaptic alpha-1-adrenoceptors; blockade of adrenoreceptors in the prostate, prostatic capsule, bladder neck and prostatic urethra
Absorption
Bioavailability: 49%
Peak Plasma Time: 8 hr
Peak Plasma Concentration: 13.6 ng/mL
AUC: 194 ng.hr/mL
Distribution
Protein Bound: 82-90%
Vd: 3.2 L/kg
Metabolism
Hepatic P450 enzyme CYP3A4
Elimination
Half-life: 5-10 hr
Excretion: Feces (69%); urine (24%)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| alfuzosin oral - | 10 mg tablet |  | |
| alfuzosin oral - | 10 mg tablet |  | |
| alfuzosin oral - | 10 mg tablet |  | |
| alfuzosin oral - | 10 mg tablet |  | |
| alfuzosin oral - | 10 mg tablet |  | |
| alfuzosin oral - | 10 mg tablet |  | |
| Uroxatral oral - | 10 mg tablet |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
alfuzosin oral
ALFUZOSIN EXTENDED-RELEASE - ORAL
(al-FUE-zoe-sin)
COMMON BRAND NAME(S): Uroxatral
USES: Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night).Alfuzosin belongs to a class of drugs known as alpha blockers.Do not use this medication to treat high blood pressure.
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking alfuzosin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth as directed by your doctor, usually once daily after a meal. This medication works best when taken with food. Taking alfuzosin on an empty stomach may make it not work as well.Swallow the tablets whole. Do not crush or chew the tablets. Doing so can release all of the drug at once, increasing the risk of side effects.Alfuzosin may cause a sudden drop in your blood pressure, which could lead to dizziness or fainting, usually within a few hours after you take it. This risk is higher when you first start taking this drug or if you restart treatment after you stop taking it. During these times, avoid situations where you may be injured if you faint.To avoid injury from dizziness or fainting, your doctor may tell you to take your first dose of alfuzosin with food at bedtime so that your body can get used to its effects.Take this medication regularly to get the most benefit from it. To help you remember, take it after the same meal each day.Tell your doctor if your condition does not improve or if it worsens.
SIDE EFFECTS: Dizziness or lightheadedness may occur. If either of these effects lasts or gets worse, tell your doctor or pharmacist promptly.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Get medical help right away if you have any very serious side effects, including: severe dizziness, fainting, fast/irregular heartbeat, chest pain.Rarely, males may have a painful or prolonged erection lasting 4 or more hours. If this occurs, stop using this drug and get medical help right away, or permanent problems could occur.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking alfuzosin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, kidney disease, heart problems (such as chest pain/angina, heart attack), low blood pressure, certain eye problems (cataracts, glaucoma).Alfuzosin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using alfuzosin, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using alfuzosin safely.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery (including cataract/glaucoma eye surgery), tell your doctor or dentist if you are taking or have ever taken this medication, and about all the other products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially dizziness and low blood pressure when getting up from a sitting or lying position, and QT prolongation (see above). These side effects can also increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: other alpha blocker drugs (such as prazosin, terazosin).If you are also taking a drug to treat erectile dysfunction-ED or pulmonary hypertension (such as sildenafil, tadalafil), your blood pressure may get too low which can lead to dizziness or fainting. Your doctor may need to adjust your medications to minimize this risk.Other medications can affect the removal of alfuzosin from your body, which may affect how alfuzosin works. Examples include azole antifungals (such as itraconazole, ketoconazole), clarithromycin, cobicistat, HIV protease inhibitors (such as lopinavir), mifepristone, nefazodone, ribociclib, ritonavir, telithromycin, among others.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness, fainting.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as prostate exams, blood pressure) should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised December 2022. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
